+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 99Years
All Genders
ID07431177

Evaluating the Safety and Effectiveness of GIA632 in Adults With Non-segmental Vitiligo Including a Long-Term Extension

Led by Novartis Pharmaceuticals · Updated on 2026-10-13

210

Participants Needed

83

Research Sites

85 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.

CONDITIONS

Brief Title

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here